The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | The potential of uproleselan in patients with AML
Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the promise of uproleselan, an antagonist of E-selectin, in patients with acute myeloid leukemia (AML), highlighting ongoing clinical trials evaluating this trial in different combinations. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
GSK, Hermavant, AvenCell, Cellularity, CTI Pharma, Kura Onc, Rigel: Advisory board
Takeda, Aptevo, Epizyme. Syntrix: DSMB
AbbVie: Steering committee
BerGenBio: Focus group
Jazz: Grand rounds
GSK, Hermavant, AvenCell, Cellularity, CTI Pharma, Kura Onc, Rigel: Advisory board
Takeda, Aptevo, Epizyme. Syntrix: DSMB
AbbVie: Steering committee
BerGenBio: Focus group
Jazz: Grand rounds
Read more...
